Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Recent Therapeutic Role of Natural Molecules against Alzheimer’s Disease
share announcement

Recent Therapeutic Role of Natural Molecules against Alzheimer’s Disease

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (21 December 2022) | Viewed by 3561

Special Issue Editors

Prof. Dr. Ilkay Erdogan Orhan

E-Mail Website
Guest Editor
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Ankara 06330, Turkey
Interests: natural products; herbal medicines; enzyme inhibition; phytotherapy; phytocosmetics
Dr. Fatma Sezer Senol Deniz

E-Mail Website
Guest Editor
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, 06330, Ankara, Turkey
Interests: pharmacognosy; natural products; herbal medicine; plant-based cosmetics

Special Issue Information

Dear Colleagues,

Neurodegenerative diseases are among the most common of deadly diseases around the world. In particular, Alzheimer’s disease (AD), which is the most common type of dementia, is progressive in nature. It is characterized by memory deficit and abnormality in behaviors as well as social skills. AD patients also frequently require extensive pharmaceutical care. Unfortunately, there is currently no cure for this disease, and only symptomatic treatment is available. Due to the complex pathophysiology of AD, no distinct pharmacotherapy has been discovered to date. Cholinesterase inhibitors as well as NMDA receptor antagonists are the drugs most prescribed at present. Thus, a certain need for novel, effective, and safe drugs still exists. A large number of ongoing studies are aimed toward finding new anti-AD drugs of natural or chemical origins. Given your expertise in this area, we are pleased to invite you to consider submitting a contribution to this Special Issue.

This Special Issue aims to scrutinize the capacity of natural molecules to serve as novel drug candidates with the ultimate aim of curing Alzheimer’s disease by acting through various mechanisms. For this Special Issue, original research articles and reviews are welcome. Research areas of interest may include (but are not limited to) the following:

  • Novel treatment strategies of Alzheimer’s disease with natural molecules
  • Cholinesterase inhibitors of natural origin
  • Natural molecules with secretase inhibitory effect
  • Natural modulators of sirtuins related to AD
  • Immunotherapeutics for AD

Prof. Dr. Ilkay Orhan
Dr. F. Sezer Senol Deniz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Alzheimer’s disease
  • natural molecules
  • dementia
  • cholinesterase inhibitors
  • cholinergic hypothesis
  • amyloid hypothesis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 2102 KiB  
Article
Characterization of Orange Peel Extract and Its Potential Protective Effect against Aluminum Chloride-Induced Alzheimer’s Disease
by Nourhan Mohammad Abd El-Aziz, Mohamed Gamal Shehata, Tawfiq Alsulami, Ahmed Noah Badr, Marwa Ramadan Elbakatoshy, Hatem Salama Ali and Sobhy Ahmed El-Sohaimy
Pharmaceuticals 2023, 16(1), 12; https://doi.org/10.3390/ph16010012 - 22 Dec 2022
Cited by 4 | Viewed by 3001
Abstract
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder without a cure. Hence, developing an effective treatment or protective agent is crucial for public health. The present study aims to characterize orange peel extract (OPE) through in vitro and in silico studies. Furthermore, it [...] Read more.
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder without a cure. Hence, developing an effective treatment or protective agent is crucial for public health. The present study aims to characterize orange peel extract (OPE) through in vitro and in silico studies. Furthermore, it examines the protective effect of OPE against experimentally-induced Alzheimer’s disease in rats. The total phenolic and flavonoid content of OPE was 255.86 ± 1.77 and 52.06 ± 1.74 (mg/100 g), respectively. Gallic acid, the common polyphenol in OPE detected by HPLC was 3388.60 μg/100 g. OPE antioxidant IC50 was 67.90 ± 1.05, 60.48 ± 0.91, and 63.70 ± 0.30 by DPPH, ABTS and Hydroxyl radical scavenging activity methods, respectively. In vitro anti-acetylcholinesterase (AChE) IC50 was 0.87 ± 0.025 mg/mL for OPE and 2.45 ± 0.001 mg/mL for gallic acid. Molecular docking analysis for human AChE (4EY7) with donepezil, gallic acid, and acetylcholine showed binding energy ΔG values of −9.47, −3.72, and −5.69 Kcal/mol, respectively. Aluminum chloride injection (70 mg/Kg/day for 6 weeks) induced Alzheimer’s-like disease in male rats. OPE (100 and 200 mg/kg/d) and gallic acid (50 mg/kg/d) were administered orally to experimental animals for 6 weeks in addition to aluminum chloride injection (as protective). OPE was found to protect against aluminum chloride-induced neuronal damage by decreasing both gene expression and activity of acetylcholinesterase (AChE) and a decrease in amyloid beta (Aβ42) protein level, thiobarbituric acid-reactive substances (TBARS), and nitric oxide (NO), and increased reduced glutathione (GSH) level and activity of the antioxidant enzymes in the brain tissues. Additionally, gene expressions for amyloid precursor protein (APP) and beta secretase enzyme (BACE1) were downregulated, whereas those for presinilin-2 (PSEN2) and beta cell lymphoma-2 (BCL2) were upregulated. Furthermore, the reverse of mitochondrial alternation and restored brain ultrastructure might underlie neuronal dysfunction in AD. In conclusion, our exploration of the neuroprotective effect of OPE in vivo reveals that OPE may be helpful in ameliorating brain oxidative stress, hence protecting from Alzheimer’s disease progression. Full article
(This article belongs to the Special Issue Recent Therapeutic Role of Natural Molecules against Alzheimer’s Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop